Canada's Cancer Breakthrough Fund Raises $30M in Year One

A groundbreaking partnership between cancer charities and venture capital investors just proved that hope and smart business can work together to save lives.

The Cancer Breakthrough Fund launched just 12 months ago with an ambitious goal: raise $30 million to help turn promising cancer research into actual treatments patients can use. This week, founding partners Lumira Ventures and the Terry Fox Foundation announced they've exceeded that target and are now aiming for $50 million.

What makes this fund special is how it works. Instead of keeping charity dollars and investment dollars separate, it brings them together with a shared mission. The Terry Fox Foundation and Canadian Cancer Society contribute their vast networks of cancer researchers and scientific expertise, while Lumira Ventures adds the business know-how to turn lab discoveries into companies that can actually deliver treatments to patients.

The fund attracted investment from leading Canadian cancer charities, impact investors, institutional backers and family offices. Every dollar represents new money flowing into Canada's life sciences sector, money specifically earmarked to help cancer patients faster.

The team has already approved funding for its first Canadian company and is reviewing a strong pipeline of cancer-focused opportunities. Each investment aims to deliver both financial returns and meaningful improvements for people fighting cancer.

Peter van der Velden, Executive Chairman of Lumira Ventures, says surpassing the initial target in just one year shows the market recognizes both the strength of mission-driven investing and the urgent need for cross-sector collaboration in Canada.

Michael Mazza, CEO of the Terry Fox Foundation, points out that great breakthroughs only help patients when scientists, entrepreneurs and investors work together. The fund breaks down traditional silos to make that collaboration happen.

Andrea Seale, CEO of the Canadian Cancer Society, emphasizes that Canadians facing cancer deserve access to the newest and best care as quickly as possible. Moving bold ideas from lab to patient requires exactly this kind of partnership.

The Ripple Effect

This model could reshape how Canada funds medical innovation. By proving that charitable missions and venture capital can work together successfully, the Cancer Breakthrough Fund creates a template other disease areas might follow. The investment from Rally Assets' Realize Fund, which uses federal Social Finance Fund dollars, signals government confidence in this approach too.

The fund's success also means more Canadian cancer innovations will stay in Canada instead of moving elsewhere for funding. That keeps jobs, expertise and economic benefits at home while speeding up patient access to new treatments.

When cancer charities, investors and researchers unite around a common goal, everyone wins, especially the patients waiting for breakthrough treatments that could save their lives.